Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by LCS.
Page 2: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
301 | 12 | 33 | 714 1998 JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 26(4):363-383 Hoglund P; Eriksson T; Bjorkman S A double-blind study of the sedative effects of the thalidomide enantiomers in humans | 11 | 15 |
302 | 13 | 66 | 727 1998 MEDICAL HYPOTHESES 50(4):313-318 Argiles JM; Carbo N; Lopez-Soriano FJ Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? | 11 | 12 |
303 | 8 | 26 | 762 1999 BIOLOGICAL & PHARMACEUTICAL BULLETIN 22(2):224-226 Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide | 11 | 17 |
304 | 20 | 42 | 786 1999 BRITISH JOURNAL OF CANCER 80(5-6):716-723 Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid | 11 | 26 |
305 | 8 | 19 | 944 2000 BONE MARROW TRANSPLANTATION 26(8):865-869 Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Wagner J; Enright H Response to thalidomide therapy in refractory chronic graft-versus-host disease | 11 | 17 |
306 | 13 | 49 | 960 2000 CLINICAL IMMUNOLOGY 97(2):109-120 Oliver SJ; Moreira A; Kaplan G Immune stimulation in scleroderma patients treated with thalidomide | 11 | 15 |
307 | 4 | 9 | 985 2000 HAEMATOLOGICA 85(10):1111-1112 Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A Low-dose thalidomide in the treatment of refractory myeloma | 11 | 19 |
308 | 4 | 12 | 1039 2000 ONCOLOGY-NEW YORK 14(12):17-20 Eisen TG Thalidomide in solid tumors: The London experience | 11 | 15 |
309 | 44 | 140 | 1183 2001 DRUG SAFETY 24(2):87-117 Clark TE; Edom N; Larson J; Lindsey LJ Thalomid (R) (Thalidomide) capsules - A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing | 11 | 14 |
310 | 8 | 10 | 1205 2001 HAEMATOLOGICA 86(10):1108-1109 Camba L; Peccatori J; Pescarollo A; Tresoldi M; Corradini P; Bregni M Thalidomide and thrombosis in patients with multiple myeloma | 11 | 12 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
311 | 6 | 18 | 1272 2001 SEMINARS IN ONCOLOGY 28(6):588-592 Blade J; Esteve J; Rosinol L; Perales M; Montoto S; Tuset M; Montserrat E Thalidomide in refractory and relapsing multiple myeloma | 11 | 13 |
312 | 18 | 36 | 1317 2002 BLOOD 99(3):834-839 Steins MB; Padro T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM Efficacy and safety of thalidomide in patients with acute myeloid leukemia | 11 | 25 |
313 | 8 | 8 | 1325 2002 BLOOD 100(6):2272-2273 Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdre L; Palareti G; Masini L; Tura S; Baccarani M Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy | 11 | 15 |
314 | 13 | 36 | 1458 2002 GUT 50(2):196-200 Bauditz J; Wedel S; Lochs H Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease | 11 | 25 |
315 | 4 | 12 | 1679 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(5):768-771 Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R Thalidomide and dexamethasone for resistant multiple myeloma | 11 | 16 |
316 | 7 | 27 | 179 1986 BRITISH JOURNAL OF DERMATOLOGY 115(3):367-370 RAMSELAAR CG; BOONE RM; KLUINNELEMANS HC THALIDOMIDE IN THE TREATMENT OF NEURO-BEHCETS SYNDROME | 10 | 20 |
317 | 1 | 59 | 222 1988 ARCHIVES OF TOXICOLOGY 61(3):165-179 MERKER HJ; HEGER W; SAMES K; STURJE H; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE-DERIVATIVES IN THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .1. EFFECTS OF 3-(1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-2,6-DIOXOPIPERIDINE (EM-12) ON SKELETAL DEVELOPMENT | 10 | 18 |
318 | 6 | 23 | 476 1995 MICROBIAL PATHOGENESIS 19(4):245-255 BURROUGHS MH; TSENOVABERKOVA L; SOKOL K; OSSIG J; TUOMANEN E; KAPLAN G EFFECT OF THALIDOMIDE ON THE INFLAMMATORY RESPONSE IN CEREBROSPINAL-FLUID IN EXPERIMENTAL BACTERIAL-MENINGITIS | 10 | 19 |
319 | 8 | 22 | 603 1997 IMMUNOPHARMACOLOGY 35(3):203-212 Shannon EJ; Morales MJ; Sandoval F Immunomodulatory assays to study structure-activity relationships of thalidomide | 10 | 13 |
320 | 0 | 0 | 615 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(14):1135-1137 Marwick C Thalidomide back - Under strict control | 10 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
321 | 6 | 26 | 663 1998 ARCHIV DER PHARMAZIE 331(1):7-12 Teubert U; Zwingenberger K; Wnendt S; Eger K 5 '-substituted thalidomide analogs as modulators of TNF-alpha | 10 | 10 |
322 | 5 | 5 | 725 1998 LANCET 352(9127):544-545 Stambe C; Wicks IP TNF alpha and response of treatment-resistant adult-onset Still's disease to thalidomide | 10 | 25 |
323 | 15 | 32 | 812 1999 IMMUNOLOGY LETTERS 68(2-3):325-332 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Selective down-regulation of T cell-and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone | 10 | 13 |
324 | 12 | 23 | 833 1999 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 28(2):214-216 Weinstein TA; Sciubba JJ; Levine J Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease | 10 | 21 |
325 | 10 | 22 | 859 1999 PEDIATRICS 103(6):1295-1297 Shek LPC; Lee YS; Lee BW; Lehman TJA Thalidomide responsiveness in an infant with Behcet's syndrome | 10 | 16 |
326 | 11 | 22 | 861 1999 PHARMACOTHERAPY 19(10):1177-1180 Horowitz SB; Stirling AL Thalidomide-induced toxic epidermal necrolysis | 10 | 10 |
327 | 4 | 4 | 949 2000 BRITISH JOURNAL OF HAEMATOLOGY 110(3):754-754 Gutheil J; Finucane D Thalidomide therapy in refractory solid tumour patients | 10 | 13 |
328 | 8 | 33 | 957 2000 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 119(1):123-129 La Maestra L; Zaninoni A; Marriott JB; Lazzarin A; Dalgleish AG; Barcellini W The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro | 10 | 18 |
329 | 16 | 22 | 991 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(3):218-222 Kyriakis KP; Kontochristopoulos GJ; Panteleos DN Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus | 10 | 17 |
330 | 27 | 36 | 1014 2000 JOURNAL OF PHARMACY AND PHARMACOLOGY 52(7):807-817 Eriksson T; Bjorkman S; Roth B; Hoglund P Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man | 10 | 17 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
331 | 10 | 18 | 1233 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(2):178-181 Facchini S; Candusso M; Martelossi S; Liubich M; Panfili E; Ventura A Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: Preliminary results | 10 | 17 |
332 | 7 | 18 | 1270 2001 SEMINARS IN ONCOLOGY 28(6):577-582 Barlogie B; Tricot G; Anaissie E Thalidomide in the management of multiple myeloma | 10 | 17 |
333 | 3 | 20 | 1324 2002 BLOOD 100(6):2263-2265 Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Opelz G; Goldschmidt H Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma | 10 | 21 |
334 | 10 | 36 | 1398 2002 BRITISH JOURNAL OF CANCER 87(10):1166-1172 Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects | 10 | 16 |
335 | 0 | 3 | 25 1981 PRACTITIONER 225(1355):721-& QUIBELL EP THE THALIDOMIDE EMBRYOPATHY - AN ANALYSIS FROM THE UK | 9 | 13 |
336 | 0 | 5 | 50 1982 NOUVELLE PRESSE MEDICALE 11(14):1080-1081 HAMZA M; CHAFFAI M; BENAYED H TREATMENT OF BEHCETS-DISEASE WITH THALIDOMIDE | 9 | 15 |
337 | 1 | 38 | 173 1985 TERATOLOGY 32(1):133-144 NEWMAN CGH TERATOGEN UPDATE - CLINICAL ASPECTS OF THALIDOMIDE EMBRYOPATHY - A CONTINUING PREOCCUPATION | 9 | 28 |
338 | 3 | 3 | 239 1988 LANCET 2(8623):1317-1317 HENEY D; LEWIS IJ; BAILEY CC THALIDOMIDE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN | 9 | 14 |
339 | 13 | 39 | 262 1989 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 20(6):1060-1063 GRINSPAN D; BLANCO GF; AGUERO S TREATMENT OF APHTHAE WITH THALIDOMIDE | 9 | 24 |
340 | 4 | 13 | 274 1990 DICP-THE ANNALS OF PHARMACOTHERAPY 24(11):1054-1056 NICOLAU DP; WEST TE THALIDOMIDE - TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN PATIENTS WITH AIDS | 9 | 17 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
341 | 1 | 4 | 286 1990 LANCET 335(8705):1591-1591 YOULE M; HAWKINS D; GAZZARD B THALIDOMIDE IN HYPERALGIC PHARYNGEAL ULCERATION OF AIDS | 9 | 11 |
342 | 0 | 6 | 310 1991 JOURNAL OF LIQUID CHROMATOGRAPHY 14(4):667-673 ABOULENEIN HY; ISLAM MR DIRECT HPLC SEPARATION OF THALIDOMIDE ENANTIOMERS USING CELLULOSE TRIS-4-METHYLPHENYL BENZOATE CHIRAL STATIONARY PHASE | 9 | 17 |
343 | 4 | 6 | 319 1992 BRITISH JOURNAL OF DERMATOLOGY 126(1):92-93 MOISSON YF; JANIER M; CIVATTE J THALIDOMIDE FOR RECURRENT ERYTHEMA MULTIFORME | 9 | 12 |
344 | 3 | 18 | 326 1992 JOURNAL OF MEDICAL GENETICS 29(10):716-723 SMITHELLS RW; NEWMAN CGH RECOGNITION OF THALIDOMIDE DEFECTS | 9 | 25 |
345 | 2 | 13 | 327 1992 JOURNAL OF PHARMACEUTICAL SCIENCES 81(7):685-689 KRENN M; GAMCSIK MP; VOGELSANG GB; COLVIN OM; LEONG KW IMPROVEMENTS IN SOLUBILITY AND STABILITY OF THALIDOMIDE UPON COMPLEXATION WITH HYDROXYPROPYL-BETA-CYCLODEXTRIN | 9 | 16 |
346 | 3 | 7 | 341 1992 TRANSPLANTATION PROCEEDINGS 24(6):2624-2625 OSTRAAT O; EKBERG H; SCHATZ H; RIESBECK K; ERIKSSON T THALIDOMIDE PROLONGS GRAFT-SURVIVAL IN RAT CARDIAC TRANSPLANTS | 9 | 9 |
347 | 4 | 4 | 443 1995 BRITISH JOURNAL OF DERMATOLOGY 132(1):168-168 MEUNIER L; MARCK Y; RIBEYRE C; MEYNADIER J ADULT CUTANEOUS LANGERHANS CELL HISTIOCYTOSIS - REMISSION WITH THALIDOMIDE TREATMENT | 9 | 20 |
348 | 5 | 76 | 544 1996 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 277(3):1649-1658 Arlen RR; Wells PG Inhibition of thalidomide teratogenicity by acetylsalicylic acid: Evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate | 9 | 15 |
349 | 9 | 20 | 545 1996 JOURNAL OF SURGICAL RESEARCH 63(1):143-146 Schmidt H; Rush B; Simonian G; Murphy T; Hsieh J; Condon M Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats | 9 | 18 |
350 | 7 | 20 | 569 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(18):1625-1631 Marriott JB; Cookson S; Carlin E; Youle M; Hawkins DA; Nelson M; Pearson P; Vaughan AN; Gazzard B; Dalgleish AG A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: Clinical tolerance and effect on activation markers and cytokines | 9 | 14 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
351 | 1 | 8 | 597 1997 DERMATOLOGY 195(4):359-361 Ferrandiz C; Carrascosa JM; Just M; Bielsa I; Ribera M Sequential combined therapy with thalidomide and narrow-band (TLO1) UVB in the treatment of prurigo nodularis | 9 | 12 |
352 | 3 | 9 | 636 1997 NATURE 385(6614):303-304 Wnendt S; Zwingenberger K Thalidomide's chirality | 9 | 16 |
353 | 7 | 20 | 672 1998 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(9):1071-1076 Niwayama S; Loh C; Turk BE; Liu JO; Miyachi H; Hashimoto Y Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-alpha production is associated with a change of mechanism of action | 9 | 11 |
354 | 2 | 25 | 704 1998 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 116(1):60-66 Partida-Sanchez S; Favila-Castillo L; Pedraza-Sanchez S; Gomez-Melgar M; Saul A; Estrada-Parra S; Estrada-Garcia I IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment | 9 | 13 |
355 | 0 | 0 | 707 1998 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 280(10):872-872 Nightingale SL Thalidomide approved for erythema nodosum leprosum | 9 | 11 |
356 | 2 | 9 | 731 1998 NATURE 396(6709):322-323 Tabin CJ A developmental model for thalidomide defects | 9 | 21 |
357 | 8 | 11 | 739 1998 REVUE DE MEDECINE INTERNE 19(3):196-198 Lair G; Marie I; Cailleux N; Blot E; Boullie MC; Courville P; Lauret P; Levesque H; Courtois H Langerhans cell histiocytosis in adult patients: cutaneous and mucous localizations improving with thalidomide | 9 | 13 |
358 | 9 | 31 | 790 1999 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 118(2):315-321 Oliver SJ; Freeman SL; Corral LG; Ocampo CJ; Kaplan G Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis | 9 | 13 |
359 | 0 | 0 | 840 1999 LANCET 354(9182):925-925 Larkin M Low-dose thalidomide seems to be effective in multiple myeloma | 9 | 14 |
360 | 5 | 11 | 866 1999 SLEEP 22(1):113-115 Kanbayashi T; Shimizu T; Takahashi Y; Kitajima T; Takahashi K; Saito Y; Hishikawa Y Thalidomide increases both REM and stage 3-4 sleep in human adults: A preliminary study | 9 | 11 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
361 | 12 | 57 | 1038 2000 ONCOLOGY-NEW YORK 14(12):11-16 Rajkumar SV Thalidomide in multiple myeloma | 9 | 17 |
362 | 7 | 35 | 1052 2000 SEMINARS IN HEMATOLOGY 37(1):26-34 Thomas DA Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders | 9 | 13 |
363 | 58 | 116 | 1072 2001 ANNALS OF MEDICINE 33(8):516-525 Ginsburg PM; Dassopoulos T; Ehrenpreis ED Thalidomide treatment for refractory Crohn's disease: a review. of the history, pharmacological mechanisms and clinical literature | 9 | 13 |
364 | 28 | 70 | 1254 2001 ONCOLOGY-NEW YORK 15(7):867-874 Rajkumar SV Current status of thalidomide in the treatment of cancer | 9 | 14 |
365 | 5 | 16 | 1289 2002 AMERICAN JOURNAL OF MEDICINE 112(5):412-413 Badros AZ; Siegel E; Bodenner D; Zangari M; Zeldis J; Barlogie B; Tricot G Hypothyroidism in patients with multiple myeloma following treatment with thalidomide | 9 | 10 |
366 | 17 | 24 | 1428 2002 CLINICAL CANCER RESEARCH 8(11):3377-3382 Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma | 9 | 13 |
367 | 17 | 24 | 1499 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):1020-1026 Bastuji-Garin S; Ochonisky S; Bouche P; Gherardi RK; Duguet C; Djerradine Z; Poli F; Revuz J; Thalidomide Neuropathy Study Grp Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients | 9 | 12 |
368 | 22 | 34 | 1554 2002 THERAPEUTIC DRUG MONITORING 24(1):104-110 Price DK; Ando Y; Kruger EA; Weiss M; Figg WD 5 '-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis | 9 | 10 |
369 | 23 | 39 | 1796 2003 MAYO CLINIC PROCEEDINGS 78(1):34-39 Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma | 9 | 21 |
370 | 2 | 17 | 114 1984 DERMATOLOGICA 168(4):182-188 GENVO MF; FAURE M; THIVOLET J THALIDOMIDE AND THALIDOMIDE WITH COLCHICINE IN THE TREATMENT OF APHTHOSIS, RECURRENT MUCOCUTANEOUS APHTHAE AND BEHCETS-DISEASE | 8 | 16 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
371 | 1 | 17 | 201 1986 ZEITSCHRIFT FUR NATURFORSCHUNG C-A JOURNAL OF BIOSCIENCES 41(11-12):1057-1061 KOCH HP; CZEJKA MJ EVIDENCE FOR THE INTERCALATION OF THALIDOMIDE INTO DNA - CLUE TO THE MOLECULAR MECHANISM OF THALIDOMIDE TERATOGENICITY | 8 | 10 |
372 | 0 | 46 | 223 1988 ARCHIVES OF TOXICOLOGY 61(3):180-191 NEUBERT D; HEGER W; MERKER HJ; SAMES K; MEISTER R EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .2. ELUCIDATION OF THE SUSCEPTIBLE PERIOD AND OF THE VARIABILITY OF EMBRYONIC STAGES | 8 | 21 |
373 | 0 | 11 | 224 1988 ARCHIVES OF TOXICOLOGY 62(2-3):200-204 SCHMAHL HJ; NAU H; NEUBERT D THE ENANTIOMERS OF THE TERATOGENIC THALIDOMIDE ANALOG EM-12 .1. CHIRAL INVERSION AND PLASMA PHARMACOKINETICS IN THE MARMOSET MONKEY | 8 | 18 |
374 | 2 | 3 | 237 1988 LANCET 2(8610):568-568 RINGDEN O; ASCHAN J; WESTERBERG L THALIDOMIDE FOR SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE | 8 | 9 |
375 | 1 | 7 | 271 1990 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 8(4):427-427 HAMZA M BEHCETS-DISEASE, PALMOPLANTAR PUSTULOSIS AND HLA-B27 TREATMENT WITH THALIDOMIDE | 8 | 9 |
376 | 0 | 1 | 280 1990 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 263(11):1474-1474 RANDALL T INVESTIGATIONAL NEW DRUG (US) ORPHAN TRIALS NOW USE THALIDOMIDE FROM 2 SOURCES | 8 | 12 |
377 | 3 | 4 | 321 1992 GENITOURINARY MEDICINE 68(6):424-425 STRAZZI S; LEBBE C; GEOFFRAY C; ABLON G; MOREL P; VEROLA O; MOLINA JM APHTHOUS ULCERS IN HIV-INFECTED PATIENTS - TREATMENT WITH THALIDOMIDE | 8 | 10 |
378 | 1 | 6 | 323 1992 INTERNATIONAL JOURNAL OF DERMATOLOGY 31(8):599-600 BERNAL JE; DURAN MM; LONDONO F; UMANA A CELLULAR IMMUNE EFFECTS OF THALIDOMIDE IN ACTINIC PRURIGO | 8 | 13 |
379 | 20 | 85 | 379 1994 ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS 13(4):177-192 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 8 | 11 |
380 | 2 | 2 | 395 1994 BRITISH MEDICAL JOURNAL 309(6952):477-477 SMITHELLS RW THALIDOMIDE MAY BE A MUTAGEN | 8 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
381 | 4 | 12 | 412 1994 LANCET 343(8895):432-433 JAKEMAN P; SMITH WCS THALIDOMIDE IN LEPROSY REACTION | 8 | 14 |
382 | 3 | 18 | 486 1995 TETRAHEDRON-ASYMMETRY 6(6):1249-1252 ROBIN S; ZHU J; GALONS H; PHAMHUY C; CLAUDE JR; TOMAS A; VIOSSAT B A CONVENIENT ASYMMETRIC-SYNTHESIS OF THALIDOMIDE | 8 | 19 |
383 | 10 | 13 | 513 1996 BONE MARROW TRANSPLANTATION 17(2):291-293 Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GAR Thalidomide responsive chronic pulmonary GVHD | 8 | 14 |
384 | 2 | 17 | 515 1996 CANCER LETTERS 101(1):21-24 Pollard M Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats | 8 | 12 |
385 | 6 | 12 | 574 1997 ANALYTICA CHIMICA ACTA 339(1-2):91-97 Simmons BR; Lush RM; Figg WD A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum | 8 | 10 |
386 | 0 | 0 | 759 1999 ARTHRITIS AND RHEUMATISM 42(10):2259-2260 Gompel A; Frances C; Piette JC; Blanc AS; Cordoliani F; Piette AM Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al | 8 | 9 |
387 | 22 | 35 | 787 1999 CANCER CHEMOTHERAPY AND PHARMACOLOGY 43:S78-S84 Dixon SC; Kruger EA; Bauer KS; Figg WD Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells | 8 | 14 |
388 | 22 | 32 | 809 1999 GASTROENTEROLOGY 117(6):1485-1488 Sands BE; Podolsky DK New life in a sleeper: Thalidomide and Crohn's disease | 8 | 25 |
389 | 5 | 17 | 814 1999 IMMUNOPHARMACOLOGY 43(1):59-64 Dunzendorfer S; Herold M; Wiedermann CJ Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide | 8 | 8 |
390 | 8 | 18 | 824 1999 JOURNAL OF CHROMATOGRAPHY B 723(1-2):255-264 Meyring M; Strickmann D; Chankvetadze B; Blaschke G; Desiderio C; Fanali S Investigation of the in vitro biotransformation of R-(+)- thalidomide by HPLC, nano-HPLC, CEC and HPLC-APCI-MS | 8 | 20 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
391 | 9 | 9 | 825 1999 JOURNAL OF CHROMATOGRAPHY B 734(2):203-210 Torano JS; Verbon A; Guchelaar HJ Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection | 8 | 8 |
392 | 12 | 20 | 988 2000 IMMUNOPHARMACOLOGY 46(2):175-179 Shannon E; Aseffa A; Pankey G; Sandoval F; Lutz B Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+cells in their blood | 8 | 8 |
393 | 4 | 17 | 1000 2000 JOURNAL OF CHILD NEUROLOGY 15(8):497-503 Schoeman JF; Springer P; Ravenscroft A; Donald PR; Bekker LG; van Rensburg AJ; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy of childhood tuberculous meningitis: Possible anti-inflammatory role | 8 | 11 |
394 | 8 | 15 | 1012 2000 JOURNAL OF INFECTIOUS DISEASES 182(3):983-987 Lokensgard JR; Hu SX; van Fenema EM; Sheng WS; Peterson PK Effect of thalidomide on chemokine production by human microglia | 8 | 11 |
395 | 4 | 7 | 1065 2001 AMERICAN JOURNAL OF GASTROENTEROLOGY 96(4):1305-1306 Ginsburg PM; Hanan I; Ehrenpreis ED Treatment of severe esophageal Crohn's disease with thalidomide | 8 | 10 |
396 | 4 | 18 | 1088 2001 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 7(5):265-273 Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WF; Weisdorf DJ Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease | 8 | 15 |
397 | 8 | 13 | 1182 2001 DRUG METABOLISM AND DISPOSITION 29(10):1355-1357 Teo SK; Harden JL; Burke AB; Noormohamed FH; Youle M; Johnson MA; Peters BS; Stirling DI; Thomas SD Thalidomide is distributed into human semen after oral dosing | 8 | 13 |
398 | 8 | 17 | 1240 2001 LEUKEMIA & LYMPHOMA 42(4):683-+ Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma | 8 | 9 |
399 | 15 | 17 | 1275 2001 SEMINARS IN ONCOLOGY 28(6):602-606 Stirling D Thalidomide: A novel template for anticancer drugs | 8 | 13 |
400 | 26 | 91 | 1313 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(3):461-479 Hashimoto Y Structural development of biological response modifiers based on thalidomide | 8 | 15 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
401 | 6 | 43 | 1412 2002 CANCER 95(8):1629-1636 Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma | 8 | 15 |
402 | 33 | 53 | 1434 2002 CURRENT OPINION IN ONCOLOGY 14(6):635-640 Raje N; Anderson KC Thalidomide and immunomodulatory drugs as cancer therapy | 8 | 14 |
403 | 4 | 4 | 1485 2002 JOURNAL OF CLINICAL ONCOLOGY 20(5):1429-1430 Nathan PD; Gore ME; Eisen TG Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma | 8 | 12 |
404 | 13 | 25 | 1492 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(2):135-139 Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease | 8 | 13 |
405 | 11 | 38 | 1518 2002 LEUKEMIA 16(9):1609-1614 Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study | 8 | 13 |
406 | 4 | 38 | 1532 2002 MICROBES AND INFECTION 4(11):1193-1202 Teo SK; Resztak KE; Scheffler MA; Kook KA; Zeldis JB; Stirling DI; Thomas SD Thalidomide in the treatment of leprosy | 8 | 10 |
407 | 8 | 17 | 1779 2003 LEUKEMIA 17(1):41-44 Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling DI; Anderson KC Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo | 8 | 17 |
408 | 0 | 39 | 44 1982 DERMATOLOGICA 165(4):355-362 SCOLARI F; HARMS M; GILARDI S THALIDOMIDE IN THE TREATMENT OF CHRONIC LUPUS-ERYTHEMATOSUS | 7 | 9 |
409 | 2 | 66 | 85 1983 HAUTARZT 34(2):66-72 HUNZIKER T; KREBS A THALIDOMIDE IN DERMATOLOGY | 7 | 7 |
410 | 6 | 13 | 144 1985 BRITISH JOURNAL OF DERMATOLOGY 113:141-144 POWELL RJ; ALLEN BR; JENKINS JS; STEELE L; HUNNEYBALL I; MAURICE PDL; LITTLEWOOD SM INVESTIGATION AND TREATMENT OF OROGENITAL ULCERATION - STUDIES ON A POSSIBLE MODE OF ACTION OF THALIDOMIDE | 7 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
411 | 5 | 15 | 163 1985 LANCET 2(8446):80-81 [Anon] THALIDOMIDE IN DERMATOLOGY AND LEPROSY | 7 | 0 |
412 | 7 | 11 | 212 1987 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 64(3):289-292 EISENBUD L; HOROWITZ I; KAY B RECURRENT APHTHOUS STOMATITIS OF THE BEHCETS TYPE - SUCCESSFUL TREATMENT WITH THALIDOMIDE | 7 | 18 |
413 | 3 | 219 | 248 1988 TERATOLOGY 38(3):241-251 BRENT RL; HOLMES LB CLINICAL AND BASIC SCIENCE LESSONS FROM THE THALIDOMIDE TRAGEDY - WHAT HAVE WE LEARNED ABOUT THE CAUSES OF LIMB DEFECTS | 7 | 37 |
414 | 6 | 33 | 259 1989 JOURNAL OF AUTOIMMUNITY 2(2):197-202 CRAIN E; MCINTOSH KR; GORDON G; PESTRONK A; DRACHMAN DB THE EFFECT OF THALIDOMIDE ON EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS | 7 | 9 |
415 | 4 | 15 | 260 1989 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 488(2):417-425 WINCKLER K; KLINKMULLER KD; SCHMAHL HJ DETERMINATION OF THE THALIDOMIDE ANALOGS 2-(2,6-DIOXOPIPERIDINE-3-YL)PHTHALIMIDINE (EM 12), 2-(2,6-DIOXOPIPERIDINE-4-YL)PHTHALIMIDINE (EM 16) AND THEIR METABOLITES IN BIOLOGICAL SAMPLES | 7 | 7 |
416 | 3 | 15 | 265 1989 TOXICOLOGY LETTERS 45(1):23-33 SCHMAHL HJ; HEGER W; NAU H THE ENANTIOMERS OF THE TERATOGENIC THALIDOMIDE ANALOG EM-12 .2. CHEMICAL-STABILITY, STEREOSELECTIVITY OF METABOLISM AND RENAL EXCRETION IN THE MARMOSET MONKEY | 7 | 17 |
417 | 0 | 6 | 278 1990 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 263(11):1467-1468 RANDALL T THALIDOMIDE BACK IN THE NEWS, BUT IN MORE FAVORABLE CIRCUMSTANCES | 7 | 21 |
418 | 0 | 1 | 330 1992 LANCET 339(8800):1057-1057 HAWKINS DF THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 7 | 8 |
419 | 28 | 38 | 354 1993 BONE MARROW TRANSPLANTATION 12:S26-S28 EHNINGER G; EGER K; STUHLER A; SCHULER U THALIDOMIDE - THE NEED FOR A NEW CLINICAL-EVALUATION OF AN OLD DRUG | 7 | 8 |
420 | 15 | 43 | 422 1994 POSTGRADUATE MEDICAL JOURNAL 70(830):860-862 GARDNERMEDWIN JM; POWELL RJ THALIDOMIDE - THE WAY FORWARD | 7 | 10 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
421 | 5 | 20 | 428 1994 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 14(3):115-122 HEGER W; SCHMAHL HJ; KLUG S; FELIES A; NAU H; MERKER HJ; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NONHUMAN PRIMATE CALLITHRIX-JACCHUS .4. TERATOGENICITY OF MU-G/KG DOSES OF THE EM12 ENANTIOMERS | 7 | 15 |
422 | 7 | 23 | 438 1995 BIOLOGICAL & PHARMACEUTICAL BULLETIN 18(9):1228-1233 SASAKI K; SHIBATA Y; HASHIMOTO Y; IWASAKI S BENZYLPHTHALIMIDES AND PHENETHYLPHTHALIMIDES WITH THALIDOMIDE-LIKE ACTIVITY ON THE PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA | 7 | 18 |
423 | 5 | 10 | 451 1995 DIGESTIVE DISEASES AND SCIENCES 40(5):1147-1148 NAUM SM; MOLLOY PJ; KANIA RJ; MCGARR J; VANTHIEL DH USE OF THALIDOMIDE IN TREATMENT AND MAINTENANCE OF IDIOPATHIC ESOPHAGEAL ULCERS IN HIV+ INDIVIDUALS | 7 | 11 |
424 | 4 | 11 | 480 1995 NATURE 375(6531):453-453 ASHBY J; TINWELL H IS THALIDOMIDE MUTAGENIC | 7 | 11 |
425 | 5 | 34 | 528 1996 HEPATOLOGY 23(6):1616-1621 LopezTalavera JC; Cadelina G; Olchowski J; Merrill W; Groszmann RJ Thalidomide inhibits tumor necrosis factor alpha decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats | 7 | 52 |
426 | 6 | 14 | 534 1996 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 111(1):13-17 SantosMendoza T; FavilaCastillo L; Oltra A; Tamariz J; Labarrios F; EstradaParra S; EstradaGarcia I Thalidomide and its metabolites have no effect on human lymphocyte proliferation | 7 | 9 |
427 | 3 | 13 | 652 1997 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 17(1):1-5 Huang PHT; McBride WG Interaction of [glutarimide-2-C-14]-thalidomide with rat embryonic DNA in vivo | 7 | 12 |
428 | 7 | 10 | 718 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(2):293-295 Warren KJ; Nopper AJ; Crosby DL Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematosus | 7 | 9 |
429 | 9 | 29 | 818 1999 INTERNATIONAL JOURNAL OF TOXICOLOGY 18(5):337-352 Teo SK; Trigg NJ; Shaw ME; Morgan JM; Thomas SD Subchronic toxicity of thalidomide in rodents after 13 weeks of oral administration | 7 | 7 |
430 | 4 | 5 | 837 1999 LANCET 353(9149):324-324 Klausner JD; Kaplan G; Haslett PAJ Thalidomide in toxic epidermal necrolysis | 7 | 8 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
431 | 69 | 136 | 868 1999 TERATOLOGY 60(5):306-321 Miller MT; Stromland K Teratogen update: Thalidomide: A review, with a focus on ocular findings and new potential uses | 7 | 19 |
432 | 85 | 116 | 881 2000 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(6-7):603-613 Laffitte E; Revuz J Thalidomide | 7 | 9 |
433 | 15 | 32 | 972 2000 ELECTROPHORESIS 21(15):3270-3279 Meyring M; Muhlenbrock C; Blaschke G Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 7 | 17 |
434 | 1 | 1 | 1030 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(5):364-364 Singhal S Antitumor activity of thalidomide in refractory multiple myeloma (vol 341, pg 1565, 1999) | 7 | 15 |
435 | 2 | 8 | 1041 2000 ONCOLOGY-NEW YORK 14(12):29-32 Govindarajan R Irinotecan and thalidomide in metastatic colorectal cancer | 7 | 12 |
436 | 99 | 191 | 1087 2001 BIODRUGS 15(10):681-703 Meierhofer C; Dunzendorfer S; Wiedermann CJ Theoretical basis for the activity of thalidomide | 7 | 14 |
437 | 31 | 67 | 1160 2001 CANCER 92(9):2364-2373 Tseng JE; Glisson BS; Khuri FR; Shin DM; Myers JN; El-Naggar AK; Roach JS; Ginsberg LE; Thall PF; Wang XM; Teddy S; Lawhorn KN; Zentgraf RE; Steinhaus GD; Pluda JM; Abbruzzese JL; Hong WK; Herbst RS Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck | 7 | 14 |
438 | 36 | 60 | 1164 2001 CELLULAR AND MOLECULAR BIOLOGY 47(7):1105-1114 Settles B; Stevenson A; Wilson K; Mack C; Ezell T; Davis MF; Taylor LD Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide | 7 | 10 |
439 | 2 | 9 | 1204 2001 HAEMATOLOGICA 86(7):772-773 Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia | 7 | 11 |
440 | 12 | 24 | 1214 2001 INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 55(9):627-631 Diggle GE Thalidomide: 40 years on | 7 | 10 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
441 | 3 | 14 | 1295 2002 ANNALS OF ONCOLOGY 13(7):1116-1119 Alexanian R; Weber D; Giralt S; Delasalle K Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy | 7 | 10 |
442 | 17 | 48 | 1310 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):31-35 Shek LPC; Lim DLC Thalidomide in Behcet's disease | 7 | 11 |
443 | 1 | 3 | 1323 2002 BLOOD 100(4):1519-1520 Leleu X; Magro L; Fawaz A; Bauters F; Facon T; Yakoub-Agha I Efficacy of a low dose of thalidomide in advanced multiple myeloma | 7 | 7 |
444 | 11 | 19 | 1475 2002 INVESTIGATIONAL NEW DRUGS 20(4):389-393 Minor DR; Monroe D; Damico LA; Meng G; Suryadevara U; Elias L A phase II study of thalidomide in advanced metastatic renal cell carcinoma | 7 | 10 |
445 | 7 | 8 | 1520 2002 LEUKEMIA & LYMPHOMA 43(2):351-354 Johnston RE; Abdalla SH Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia | 7 | 9 |
446 | 13 | 29 | 1534 2002 NEUROLOGY 59(12):1872-1875 Chaudhry V; Cornblath DR; Corse A; Freimer M; Simmons-O'Brien E; Vogelsang G Thalidomide-induced neuropathy | 7 | 9 |
447 | 18 | 42 | 1604 2003 BLOOD 102(1):69-77 Mileshkin L; Biagi JJ; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Lillie K; Smith JG; Zeldis JB; Prince HM Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age | 7 | 10 |
448 | 22 | 28 | 1692 2003 CANCER RESEARCH 63(3):593-599 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins | 7 | 14 |
449 | 26 | 38 | 1698 2003 CLINICAL CANCER RESEARCH 9(5):1680-1688 Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Muller G; Ching LM Thalidomide metabolites in mice and patients with multiple myeloma | 7 | 8 |
450 | 0 | 20 | 10 1981 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 98(4):1029-1034 BRAUN AG; DAILEY JP THALIDOMIDE METABOLITE INHIBITS TUMOR-CELL ATTACHMENT TO CONCANAVALIN A COATED SURFACES | 6 | 16 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
451 | 0 | 18 | 23 1981 PATHOLOGIE BIOLOGIE 29(10):601-604 FAURE M; LEJEUNE JP; GAUCHERAND M; THIVOLET J PMN LEUKOCYTES CHEMOTAXIS - INHIBITION BY THALIDOMIDE | 6 | 9 |
452 | 0 | 0 | 46 1982 EEG-EMG-ZEITSCHRIFT FUR ELEKTROENZEPHALOGRAPHIE ELEKTROMYOGRAPHIE UND VERWANDTE GEBIETE 13(4):167-170 LUDOLPH A; MATZ DR ELECTRONEUROGRAPHIC STUDIES IN PATIENTS UNDER THALIDOMIDE THERAPY OF LUPUS ERYTHEMATODES DISCOIDES | 6 | 1 |
453 | 0 | 2 | 115 1984 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 8(2):196-196 ROGE J; TESTAS P THALIDOMIDE IN BEHCETS SYNDROME | 6 | 7 |
454 | 0 | 4 | 121 1984 LANCET 2(8394):98-99 NIELSEN H; BENNIKE T THALIDOMIDE ENHANCES DEFECTIVE MONOCYTE FUNCTION IN LEPROMATOUS LEPROSY | 6 | 8 |
455 | 1 | 35 | 182 1986 CLINICS IN PERINATOLOGY 13(3):555-573 NEWMAN CGH THE THALIDOMIDE SYNDROME - RISKS OF EXPOSURE AND SPECTRUM OF MALFORMATIONS | 6 | 19 |
456 | 3 | 10 | 188 1986 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 14(2):282-283 ARONSON IK; WEBER L; WEST D; BUYS C; REDER A; ANTEL J THALIDOMIDE AND LYMPHOCYTE FUNCTION | 6 | 6 |
457 | 3 | 32 | 205 1987 ARCHIVES OF TOXICOLOGY 60(5):376-381 STERZ H; NOTHDURFT H; LEXA P; OCKENFELS H TERATOLOGIC STUDIES ON THE HIMALAYAN RABBIT - NEW ASPECTS OF THALIDOMIDE-INDUCED TERATOGENESIS | 6 | 10 |
458 | 2 | 15 | 225 1988 ARCHIVES OF TOXICOLOGY 62(2-3):205-208 HEGER W; KLUG S; SCHMAHL HJ; NAU H; MERKER HJ; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES ON THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .3. TERATOGENIC POTENCY OF THE EM-12 ENANTIOMERS | 6 | 13 |
459 | 0 | 3 | 228 1988 BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 26(5):P623-P623 HAGUE D; SMITH RL ENIGMATIC PROPERTIES OF (+/-)-THALIDOMIDE - AN EXAMPLE OF A STABLE RACEMIC COMPOUND | 6 | 7 |
460 | 0 | 6 | 233 1988 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 56(4):625-625 SALAFIA A; KHARKAR RD THALIDOMIDE AND EXFOLIATIVE DERMATITIS | 6 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
461 | 2 | 4 | 289 1990 MEDICAL JOURNAL OF AUSTRALIA 152(7):382-383 GEORGHIOU PR; KEMP RJ HIV-ASSOCIATED ESOPHAGEAL ULCERS TREATED WITH THALIDOMIDE | 6 | 9 |
462 | 6 | 38 | 293 1990 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 10(4):281-294 HUANG PHT; MCBRIDE WG THALIDOMIDE INDUCED ALTERATION IN SECONDARY STRUCTURE OF RAT EMBRYONIC DNA INVIVO | 6 | 12 |
463 | 2 | 8 | 302 1991 BRITISH MEDICAL JOURNAL 302(6792):1603-1604 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 6 | 7 |
464 | 3 | 6 | 340 1992 TRANSPLANTATION PROCEEDINGS 24(6):2560-2561 ERIKSSON T; RIESBECK K; OSTRAAT O; EKBERG H; BJORKMAN S DRUG EXPOSURE AND FLOW-CYTOMETRY ANALYSES IN A THALIDOMIDE TREATMENT SCHEDULE THAT PROLONGS RAT CARDIAC GRAFT-SURVIVAL | 6 | 7 |
465 | 4 | 5 | 353 1993 BONE MARROW TRANSPLANTATION 11(3):251-252 LOPEZ J; ULIBARRENA C; GARCIALARANA J; ODRIOZOLA J; DEOTEYZA JP; SASTRE JL; NAVARRO JL THALIDOMIDE AS THERAPY FOR INTESTINAL CHRONIC GVHD | 6 | 9 |
466 | 7 | 25 | 410 1994 JOURNAL OF HEPATOLOGY 21(4):496-499 MCCORMICK PA; SCOTT F; EPSTEIN O; BURROUGHS AK; SCHEUER PJ; MCINTYRE N THALIDOMIDE AS THERAPY FOR PRIMARY BILIARY-CIRRHOSIS - A DOUBLE-BLIND PLACEBO-CONTROLLED PILOT-STUDY | 6 | 11 |
467 | 7 | 18 | 429 1995 ACTA NEUROPATHOLOGICA 89(5):415-419 SCHRODER JM; SELLHAUS B; WOHRMANN T; KOGEL B; ZWINGENBERGER K INHIBITORY EFFECTS OF THALIDOMIDE ON CELLULAR PROLIFERATION, ENDONEURIAL EDEMA AND MYELIN PHAGOCYTOSIS DURING EARLY WALLERIAN DEGENERATION | 6 | 9 |
468 | 6 | 10 | 448 1995 CLINICAL BIOCHEMISTRY 28(4):467-470 LYON AW; DURAN G; RAISYS VA DETERMINATION OF THALIDOMIDE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - METHODOLOGICAL STRATEGY FOR CLINICAL-TRIALS | 6 | 7 |
469 | 4 | 6 | 449 1995 CLINICAL CHEMISTRY 41(8):1199-1199 HUUPPONEN R; PYYKKO K STABILITY OF THALIDOMIDE IN HUMAN PLASMA | 6 | 8 |
470 | 2 | 31 | 458 1995 FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY 12(3-4):165-174 GEIST C; WOHRMANN T; SCHNEIDER J; ZWINGENBERGER K EFFECTS OF THALIDOMIDE ON THE LOCAL SHWARTZMAN REACTION IN MICE AND RABBITS | 6 | 8 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
471 | 3 | 13 | 497 1996 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 123(6-7):375-377 Cherouati K; Claudy A; Souteyrand P; Cambazard F; Vaillant L; Moulin G; Crickx B; Morel P; Lamorelle A; Revuz J Thalidomide treatment of chronic erythema multiforme recurrent and continuous variants. A retrospective study of 26 patients. | 6 | 7 |
472 | 10 | 28 | 516 1996 CHIRALITY 8(1):11-17 Reepmeyer JC Separation of R-and S-thalidomide by reversed-phase HPLC with beta-cyclodextrin in the mobile phase | 6 | 18 |
473 | 12 | 27 | 578 1997 BIOCHEMICAL PHARMACOLOGY 53(10):1553-1557 Nicolai S; Sies H; Stahl W Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts | 6 | 11 |
474 | 6 | 22 | 588 1997 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 108(3):428-431 Hauschild A; Kroeger H; Mitchison NA; Ugrinovic S; Zwingenberger K Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift | 6 | 12 |
475 | 5 | 5 | 590 1997 CLINICAL CHEMISTRY 43(6):1094-1095 Eriksson T; Bjorkman S Handling of blood samples for determination of thalidomide | 6 | 6 |
476 | 0 | 30 | 721 1998 LANCET 351(9110):1197-1199 Dally A Thalidomide: was the tragedy preventable? | 6 | 16 |
477 | 25 | 52 | 830 1999 JOURNAL OF INVESTIGATIVE DERMATOLOGY 113(5):720-724 Nasca MR; O'Toole EA; Palicharla P; West DP; Woodley DT Thalidomide increases human keratinocyte migration and proliferation | 6 | 15 |
478 | 8 | 40 | 862 1999 REPRODUCTIVE TOXICOLOGY 13(6):547-554 Hansen JM; Carney EW; Harris C Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro | 6 | 11 |
479 | 4 | 4 | 888 2000 ARCHIVES OF DERMATOLOGY 136(12):1442-1443 Camisa C; Popovsky JL Effective treatment of oral erosive lichen planus with thalidomide | 6 | 11 |
480 | 13 | 33 | 895 2000 BIOPHARMACEUTICS & DRUG DISPOSITION 21(1):33-40 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women | 6 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
481 | 23 | 45 | 952 2000 CANCER CHEMOTHERAPY AND PHARMACOLOGY 46(2):135-141 Kestell P; Zhao LL; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide | 6 | 21 |
482 | 8 | 8 | 1010 2000 JOURNAL OF INFECTIOUS DISEASES 182(2):639-639 Gori A; Rossi MC; Trabattoni D; Marchetti G; Fusi ML; Molteni C; Clerici M; Franzetti F Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection | 6 | 7 |
483 | 7 | 16 | 1040 2000 ONCOLOGY-NEW YORK 14(12):25-28 Hwu WJ New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide | 6 | 14 |
484 | 1 | 2 | 1044 2000 PALLIATIVE MEDICINE 14(1):77-78 Calder K; Bruera E Thalidomide for night sweats in patients with advanced cancer | 6 | 7 |
485 | 16 | 59 | 1047 2000 QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS 93(5):305-311 Davey PP; Ashrafian H New therapies for heart failure: is thalidomide the answer? | 6 | 9 |
486 | 9 | 27 | 1048 2000 SEMINARS IN HEMATOLOGY 37(1):1-4 Anderson KC Thalidomide: Therapeutic potential in hematologic malignancies | 6 | 8 |
487 | 3 | 37 | 1055 2000 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(1):35-47 Fort DJ; Stover EL; Bantle JA; Finch RA Evaluation of the developmental toxicity of thalidomide using Frog Embryo Teratogenesis Assay-Xenopus (FETAX): Biotransformation and detoxification | 6 | 8 |
488 | 18 | 26 | 1222 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3593-3595 Rajkumar SV; Kyle RA Thalidomide in the treatment of plasma cell malignancies | 6 | 7 |
489 | 11 | 18 | 1225 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(10):1091-1097 Aweeka F; Trapnell C; Chernoff M; Jayewardene A; Spritzler J; Bellibas SE; Lizak P; Jacobson J Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251 | 6 | 7 |
490 | 29 | 42 | 1242 2001 LUPUS 10(3):188-192 Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GRV Update on therapy - thalidomide in the treatment of lupus | 6 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
491 | 1 | 3 | 1293 2002 ANNALS OF INTERNAL MEDICINE 136(9):711-711 Escudier B; Lassau N; Leborgne S; Angevin E; Laplanche A Thalidomide and venous thrombosis | 6 | 9 |
492 | 30 | 71 | 1305 2002 BIOLOGICAL & PHARMACEUTICAL BULLETIN 25(5):597-604 Marks MG; Shi JD; Fry MO; Xiao ZL; Trzyna M; Pokala V; Ihnat MA; Li PK Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation | 6 | 9 |
493 | 9 | 19 | 1394 2002 BONE MARROW TRANSPLANTATION 29(7):577-580 Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR Myeloma - Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 6 | 7 |
494 | 13 | 33 | 1411 2002 CANCER 95(4):758-765 Daliani DD; Papandreou CN; Thall PF; Wang XM; Perez C; Oliva R; Pagliaro L; Amato R A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma | 6 | 11 |
495 | 39 | 67 | 1479 2002 JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 6(2):160-174 Kumar S; Witzig TE; Rajkumar SV Thalidomide as an anti-cancer agent | 6 | 10 |
496 | 20 | 24 | 1487 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2607-2609 Eisen T Thalidomide in solid malignancies | 6 | 12 |
497 | 15 | 47 | 1602 2003 BLOOD 101(7):2534-2541 Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder GE; Reeder T; Zeldis JB; Tefferi A A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia | 6 | 10 |
498 | 1 | 17 | 136 1985 ACTA NEUROPATHOLOGICA 65(3-4):285-292 SCHRODER JM; MATTHIESEN T EXPERIMENTAL THALIDOMIDE NEUROPATHY - THE MORPHOLOGICAL CORRELATE OF REDUCED CONDUCTION-VELOCITY | 5 | 7 |
499 | 2 | 3 | 140 1985 ARTHRITIS AND RHEUMATISM 28(7):836-836 MIYACHI Y A POSSIBLE MECHANISM OF ACTION OF THALIDOMIDE ON RHEUMATOID-ARTHRITIS | 5 | 5 |
500 | 3 | 13 | 166 1985 LEPROSY REVIEW 56(4):297-301 SHANNON EJ; TRUMAN RW; CHRISTY SA; BROWN LM; VADIEE R; HASTINGS RC EFFECT OF THALIDOMIDE ON INDUCTION OF ANTIBODY-SYNTHESIS IN MICE TO THE T-INDEPENDENT ANTIGEN, DNP-FICOLL | 5 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
501 | 6 | 30 | 170 1985 REVUE NEUROLOGIQUE 141(11):719-728 CHAPON F; LECHEVALIER B; DASILVA DC; RIVRAIN Y; DUPUY B; DESCHAMPS P THALIDOMIDE INDUCED NEUROPATHY | 5 | 8 |
502 | 6 | 15 | 180 1986 BRITISH JOURNAL OF DERMATOLOGY 115(6):677-680 MAURICE PDL; BARKLEY ASJ; ALLEN BR THE EFFECT OF THALIDOMIDE ON ARACHIDONIC-ACID METABOLISM IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES AND PLATELETS | 5 | 5 |
503 | 0 | 2 | 213 1987 PRENATAL DIAGNOSIS 7(4):295-298 GOLLOP TR; EIGIER A PRENATAL-DIAGNOSIS OF THALIDOMIDE SYNDROME | 5 | 6 |
504 | 8 | 14 | 275 1990 EUROPEAN SURGICAL RESEARCH 22(6):336-339 EMRE S; SUMRANI N; HONG J BENEFICIAL EFFECT OF THALIDOMIDE AND CICLOSPORIN COMBINATION IN HETEROTOPIC CARDIAC TRANSPLANTATION IN RATS | 5 | 5 |
505 | 3 | 10 | 303 1991 BRITISH MEDICAL JOURNAL 303(6800):470-470 WATERS MFR USE OF THALIDOMIDE IN LEPROSY | 5 | 5 |
506 | 0 | 0 | 308 1991 INTERNATIONAL JOURNAL OF STD & AIDS 2(5):369-370 FULLER GN; JACOBS JM; GUILOFF RJ THALIDOMIDE, PERIPHERAL NEUROPATHY AND AIDS | 5 | 7 |
507 | 4 | 5 | 337 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(10):735-735 CRAWFORD CL THALIDOMIDE NEUROPATHY | 5 | 6 |
508 | 7 | 10 | 350 1993 ARCHIVES OF INTERNAL MEDICINE 153(4):534-534 VICENTE T; ORTEGA A; MUNOZ P; DIAZ MD; BOUZA E INVITRO ACTIVITY OF THALIDOMIDE AGAINST MYCOBACTERIUM-AVIUM COMPLEX | 5 | 6 |
509 | 0 | 0 | 372 1993 PEDIATRIC DERMATOLOGY 10(3):283-285 MENNI S; IMONDI D; BRANCALEONE W; CROCI S RECURRENT GIANT APHTHOUS ULCERS IN A CHILD - PROTRACTED TREATMENT WITH THALIDOMIDE | 5 | 10 |
510 | 1 | 1 | 396 1994 BRITISH MEDICAL JOURNAL 309(6956):741-741 KIDA M THALIDOMIDE MAY NOT BE A MUTAGEN | 5 | 7 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
511 | 5 | 34 | 406 1994 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 16(4):717-729 SHANNON EJ; HOWE RC; MCLEAN K; HASTINGS RC THALIDOMIDE DOES NOT PERTURB CD2, CD4, CD5, CD8, HLA-DR, OR HLA-A, HLA-B, HLA-C MOLECULES IN-VITRO ON THE MEMBRANES OF CELLS WITH IMMUNE POTENTIAL | 5 | 5 |
512 | 8 | 14 | 461 1995 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 233(2):90-93 GUEXCROSIER Y; PITTET N; HERBORT CP THE EFFECT OF THALIDOMIDE AND SUPIDIMIDE ON ENDOTOXIN-INDUCED UVEITIS IN RATS | 5 | 6 |
513 | 6 | 14 | 468 1995 JOURNAL OF LIQUID CHROMATOGRAPHY 18(2):297-309 DELON A; FAVRELIERE S; COUET W; COURTOIS PH; BOUQUET S RAPID AND SENSITIVE DETERMINATION OF THALIDOMIDE IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 5 | 5 |
514 | 0 | 0 | 473 1995 LANCET 346(8985):1289-1289 THOMPSON C THALIDOMIDE EFFECTIVE FOR AIDS-RELATED ORAL ULCERS | 5 | 10 |
515 | 9 | 12 | 494 1996 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 53(4):368-& Weidle PJ Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus | 5 | 5 |
516 | 7 | 9 | 521 1996 DERMATOLOGY 193(4):321-323 Bonnetblanc JM; Royer C; Bedane C Thalidomide and recurrent aphthous stomatitis: A follow-up study | 5 | 10 |
517 | 10 | 14 | 556 1996 PEDIATRIC INFECTIOUS DISEASE JOURNAL 15(5):465-467 DeVincenzo JP; Burchet SK Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers | 5 | 7 |
518 | 8 | 21 | 606 1997 INFLAMMATION RESEARCH 46(10):392-397 Schneider J; Bruckmann W; Zwingenberger K Extravasation of leukocytes assessed by intravital microscopy: Effect of thalidomide | 5 | 13 |
519 | 0 | 0 | 627 1997 JOURNAL OF THE NATIONAL CANCER INSTITUTE 89(20):1480-1481 Saphir A Jekyll and Hyde: A new license for thalidomide? | 5 | 7 |
520 | 3 | 24 | 662 1998 ANTICANCER RESEARCH 18(6A):4409-4413 Browne WL; Wilson WR; Baguley BC; Ching LM Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid | 5 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
521 | 5 | 15 | 671 1998 BIOLOGICAL & PHARMACEUTICAL BULLETIN 21(6):638-640 Ishikawa M; Kanno S; Takayanagi M; Takayanagi Y; Sasaki K Thalidomide promotes the release of tumor necrosis factor-alpha (TNF-alpha) and lethality by lipopolysaccharide in mice | 5 | 6 |
522 | 2 | 5 | 692 1998 CLINICAL INFECTIOUS DISEASES 26(1):184-185 Gori A; Franzetti F; Marchetti G; Rossi C; Fusi ML; Ruzzante S; Clerici M Clinical and immunological improvement in a patient who received thalidomide treatment for refractory Mycobacterium avium complex infection | 5 | 7 |
523 | 9 | 10 | 695 1998 DRUG SAFETY 19(5):339-341 Smithells D Does thalidomide cause second generation birth defects? | 5 | 5 |
524 | 10 | 55 | 737 1998 PAIN 74(1):83-91 Sommer C; Marziniak M; Myers RR The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve | 5 | 55 |
525 | 6 | 24 | 748 1999 AMERICAN JOURNAL OF PUBLIC HEALTH 89(1):98-101 Annas GJ; Elias S Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century | 5 | 7 |
526 | 6 | 11 | 793 1999 CLINICAL NEUROPHYSIOLOGY 110(4):735-739 Sadoh DR; Hawk JLM; Panayiotopoulos CP F-chronodispersion in patients on thalidomide | 5 | 5 |
527 | 3 | 44 | 797 1999 CURRENT EYE RESEARCH 19(6):483-490 Spraul CW; Kaven C; Kampmeier J; Lang GK; Lang GE Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro | 5 | 9 |
528 | 2 | 5 | 798 1999 DERMATOLOGY 199(2):195-195 Bez C; Lodi G; Sardella A; Della Volpe A; Carrassi A Oral lichenoid lesions after thalidomide treatment | 5 | 5 |
529 | 9 | 23 | 799 1999 DRUG SAFETY 21(3):161-169 Lary JM; Daniel KL; Erickson JD; Roberts HE; Moore CA The return of thalidomide - Can birth defects be prevented? | 5 | 10 |
530 | 6 | 15 | 829 1999 JOURNAL OF INFECTIOUS DISEASES 180(1):216-219 Meierhofer C; Dunzendorfer S; Wiederman CJ Protein kinase C-dependent effects on leukocyte migration of thalidomide | 5 | 10 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
531 | 3 | 14 | 843 1999 MEDICAL HYPOTHESES 53(1):76-77 Sastry PSRK Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis | 5 | 7 |
532 | 3 | 13 | 856 1999 ORGANIC PROCESS RESEARCH & DEVELOPMENT 3(2):139-140 Muller GW; Konnecke WE; Smith AM; Khetani VD A concise two-step synthesis of thalidomide | 5 | 12 |
533 | 13 | 35 | 864 1999 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):305-311 Monastirli A; Georgiou S; Bolsen K; Pasmatzi E; Papapanagiotou A; Goerz G; Kalofoutis A; Merk HF; Tsambaos D Treatment of porphyria cutanea tarda with oral thalidomide | 5 | 7 |
534 | 5 | 5 | 872 2000 AIDS 14(12):1859-1861 Gori A; Rossi MC; Marchetti G; Trabattoni D; Molteni C; Cogliati M; Bandera A; Clerici M; Franzetti F Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease | 5 | 7 |
535 | 19 | 38 | 886 2000 ANTI-CANCER DRUGS 11(10):787-791 Adlard JW Thalidomide in the treatment of cancer | 5 | 11 |
536 | 1 | 1 | 950 2000 BRITISH JOURNAL OF HAEMATOLOGY 111(3):986-986 Myers B; Crouch D; Dolan G Thalidomide treatment in advanced refractory myeloma | 5 | 5 |
537 | 4 | 8 | 982 2000 GASTROENTEROLOGY 119(2):596-596 Fishman SJ; Feins NR; D'Amato RJ; Folkman J Thalidomide therapy for Crohn's disease | 5 | 12 |
538 | 7 | 16 | 1022 2000 MAYO CLINIC PROCEEDINGS 75(8):842-844 Federman GL; Federman DG Recalcitrant pyoderma gangrenosum treated with thalidomide | 5 | 13 |
539 | 4 | 5 | 1027 2000 MUSCLE & NERVE 23(8):1301-1302 Rao DG; Kane NM; Oware A Thalidomide neuropathy: Role of F-wave monitoring | 5 | 5 |
540 | 3 | 15 | 1050 2000 SEMINARS IN HEMATOLOGY 37(1):15-21 Munshi NC; Desikan KR; Barlogie B Clinical experience with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies | 5 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
541 | 5 | 42 | 1053 2000 SEMINARS IN HEMATOLOGY 37(1):35-39 Alexanian R; Anderson KC; Barlogie B; Stirling DI; Thomas DA Thalidomide in hematologic malignancies: Future directions | 5 | 5 |
542 | 18 | 37 | 1061 2000 TOXICOLOGY AND APPLIED PHARMACOLOGY 165(3):237-244 Karrow NA; McCay JA; Brown RD; Musgrove DL; Pettit DA; Munson AE; Germolec DR; White KL Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice | 5 | 8 |
543 | 7 | 12 | 1067 2001 AMERICAN JOURNAL OF HEMATOLOGY 66(4):300-302 Fowler R; Imrie K Thalidomide-associated hepatitis: A case report | 5 | 6 |
544 | 11 | 12 | 1071 2001 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(5):611-613 Estines O; Revuz J; Wolkenstein P; Bressieux JM; Roujeau JC; Cosnes A Sarcoidosis: thalidomide treatment in ten patients | 5 | 6 |
545 | 3 | 10 | 1166 2001 CHILDS NERVOUS SYSTEM 17(6):370-372 Schoeman JF; Ravenscroft A; Hartzenberg HB Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess | 5 | 5 |
546 | 3 | 3 | 1169 2001 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 19(3):360-361 Scoville CD Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis | 5 | 5 |
547 | 13 | 23 | 1213 2001 INTERNATIONAL IMMUNOPHARMACOLOGY 1(1):49-61 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B | 5 | 8 |
548 | 2 | 3 | 1262 2001 PRESSE MEDICALE 30(20):1008-1009 Pouaha J; Martin S; Trechot P; Truchetet F; Barbaud A; Schmutz JL Thalidomide and thrombosis: three cases | 5 | 5 |
549 | 11 | 41 | 1266 2001 RHEUMATOLOGY 40(8):933-938 Kari JA; Shah V; Dillon MJ Behcet's disease in UK children: clinical features and treatment including thalidomide | 5 | 16 |
550 | 7 | 21 | 1271 2001 SEMINARS IN ONCOLOGY 28(6):583-587 Kyle RA; Rajkumar SV Therapeutic application of thalidomide in multiple myeloma | 5 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
551 | 23 | 52 | 1278 2001 TOXICOLOGICAL SCIENCES 59(1):160-168 Teo SK; Evans MG; Brockman MJ; Ehrhart J; Morgan JM; Stirling DI; Thomas SD Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs | 5 | 5 |
552 | 17 | 42 | 1308 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):13-19 Sampaio EP; Hernandez MO; Carvalho DS; Sarno EN Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M-leprae-induced TNF alpha production in vitro | 5 | 6 |
553 | 50 | 93 | 1311 2002 BIOMEDICINE & PHARMACOTHERAPY 56(3):115-128 Richardson P; Hideshima T; Anderson K Thalidomide in multiple myeloma | 5 | 6 |
554 | 30 | 45 | 1312 2002 BIOMEDICINE & PHARMACOTHERAPY 56(4):194-199 Ng SSW; Brown M; Figg WD Thalidomide, an antiangiogenic agent with clinical activity in cancer | 5 | 6 |
555 | 13 | 15 | 1496 2002 JOURNAL OF INFECTIOUS DISEASES 185(9):1359-1363 Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H; Natl Inst Allergy Infect Dis AIDS Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267 | 5 | 5 |
556 | 4 | 17 | 1539 2002 ONCOLOGY-NEW YORK 16(4):23-26 Govindarajan R Irinoteean/Thalidomide in metastatic colorectal cancer | 5 | 6 |
557 | 5 | 31 | 1551 2002 SEMINARS IN ONCOLOGY 29(6):34-38 Durie BGM Low-dose thalidomide in myeloma: Efficacy and biologic significance | 5 | 8 |
558 | 5 | 12 | 1677 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(1):101-103 Steurer M; Sudmeier I; Stauder R; Gastl G Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha | 5 | 7 |
559 | 19 | 40 | 1682 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(4):607-616 Kropff MH; Lang N; Bisping G; Domine N; Innig G; Hentrich M; Mitterer M; Sudhoff T; Fenk R; Straka C; Heinecke A; Koch OM; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma | 5 | 9 |
560 | 16 | 25 | 1702 2003 CLINICAL LYMPHOMA 3(4):241-246 Seldin DC; Choufani EB; Dember LM; Wiesman JF; Berk JL; Falk RH; O'Hara C; Fennessey S; Finn KT; Wright DG; Skinner M; Sanchorawala V Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis | 5 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
561 | 0 | 0 | 32 1981 TERATOLOGY 23(2):A65-A65 THEISEN CT; MCGREGOR EE FURTHER OBSERVATIONS ON THE DEVELOPMENT OF THALIDOMIDE INDUCED LIMB DEFORMITIES | 4 | 7 |
562 | 0 | 0 | 54 1982 TERATOLOGY 25(2):A47-A47 HELM FC; FRANKUS E CHEMICAL-STRUCTURE AND TERATOGENIC ACTIVITY OF THALIDOMIDE-RELATED COMPOUNDS | 4 | 4 |
563 | 2 | 12 | 88 1983 HAUTARZT 34(9):435-436 KNOP J; MACHER E THALIDOMIDE IN THE TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS | 4 | 4 |
564 | 2 | 4 | 95 1983 PRESSE MEDICALE 12(47):3007-3007 PRIGENT F; OUAZZANI W SARCOIDOSIS OF THE SKIN - TREATMENT WITH THALIDOMIDE | 4 | 4 |
565 | 4 | 38 | 96 1983 SEMAINE DES HOPITAUX 59(45):3101-3104 BELAUBE P; GARCIN G; MARCHAND JP; PRIVAT Y SHOULD THALIDOMIDE BE REHABILITATED | 4 | 7 |
566 | 0 | 0 | 104 1984 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 111(3):285-286 SCHNITZLER L THALIDOMIDE IN HAILEY-HAILEY DISEASE - GOOD BUT PALLIATIVE RESULTS | 4 | 11 |
567 | 1 | 144 | 120 1984 JOURNAL OF THEORETICAL BIOLOGY 110(3):461-486 SHULL GE DIFFERENTIAL INHIBITION OF PROTEIN-SYNTHESIS - A POSSIBLE BIOCHEMICAL-MECHANISM OF THALIDOMIDE TERATOGENESIS | 4 | 6 |
568 | 1 | 14 | 124 1984 MUSCLE & NERVE 7(5):362-368 SCHWAB BW; AREZZO JC; PALDINO AM; FLOHE L; MATTHIESSEN T; SPENCER PS RABBIT SURAL NERVE RESPONSES TO CHRONIC TREATMENT WITH THALIDOMIDE AND SUPIDIMIDE | 4 | 6 |
569 | 3 | 14 | 174 1986 ACTA PATHOLOGICA MICROBIOLOGICA ET IMMUNOLOGICA SCANDINAVICA SECTION C-IMMUNOLOGY 94(6):233-237 NIELSEN H; VALERIUS NH THALIDOMIDE ENHANCES SUPEROXIDE ANION RELEASE FROM HUMAN POLYMORPHONUCLEAR AND MONONUCLEAR LEUKOCYTES | 4 | 7 |
570 | 4 | 28 | 186 1986 FOOD AND DRUG LAW JOURNAL 41(4):458-466 SHERMAN M; STRAUSS S THALIDOMIDE - A 25-YEAR PERSPECTIVE | 4 | 14 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
571 | 21 | 64 | 263 1989 MEDICAL HYPOTHESES 30(2):105-109 GUNZLER V THALIDOMIDE - A THERAPY FOR THE IMMUNOLOGICAL CONSEQUENCES OF HIV INFECTION | 4 | 6 |
572 | 1 | 33 | 346 1993 ACTA OPHTHALMOLOGICA 71(2):238-245 STROMLAND K; MILLER MT THALIDOMIDE EMBRYOPATHY - REVISITED 27 YEARS LATER | 4 | 12 |
573 | 11 | 35 | 370 1993 MOLECULAR AND CELLULAR BIOCHEMISTRY 129(2):195-200 WEGLICKI WB; STAFFORD RE; DICKENS BF; MAK IT; CASSIDY MM; PHILLIPS TM INHIBITION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE IN MAGNESIUM-DEFICIENCY | 4 | 9 |
574 | 4 | 10 | 383 1994 ARCHIVES OF TOXICOLOGY 68(3):203-205 KLUG S; FELIES A; STURJE H; NOGUEIRA AC; NEUBERT R; FRANKUS E EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NONHUMAN PRIMATE CALLITHRIX-JACCHUS .5. LACK OF TERATOGENIC EFFECTS OF PHTHALIMIDOPHTHALIMIDE | 4 | 7 |
575 | 5 | 5 | 391 1994 BRITISH MEDICAL JOURNAL 308(6941):1437-1438 CRAWFORD CL SAFETY OF THALIDOMIDE | 4 | 4 |
576 | 3 | 5 | 397 1994 BRITISH MEDICAL JOURNAL 309(6966):1442-1442 TENCONI R; CLEMENTI M; NOTARI L; VASCO VRLO AMNIOTIC BAND SEQUENCE IN CHILD OF THALIDOMIDE VICTIM | 4 | 6 |
577 | 0 | 1 | 413 1994 LANCET 343(8900):795-796 CUTLER J THALIDOMIDE REVISITED | 4 | 5 |
578 | 2 | 5 | 414 1994 LANCET 343(8904):1041-1041 JONES GRN THALIDOMIDE - 35 YEARS ON AND STILL DEFORMING | 4 | 5 |
579 | 3 | 5 | 415 1994 LANCET 344(8916):196-197 TEIXEIRA F; HOJYO MT; ARENAS R; VEGA ME; CORTES R; ORTIZ A; DOMINGUEZ L THALIDOMIDE - CAN IT CONTINUE TO BE USED | 4 | 4 |
580 | 16 | 45 | 426 1994 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 40(5):535-542 ARALACHAVES M; VILANOVA M; RIBEIRO A; PINTO J IMMUNOSTIMULATORY EFFECT OF THALIDOMIDE IN NORMAL C57BL/6 MICE IS COMPATIBLE WITH STIMULATION OF A HIGHLY CONNECTED CENTRAL IMMUNE-SYSTEM .1. | 4 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
581 | 8 | 26 | 427 1994 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 40(5):543-548 VILANOVA M; RIBEIRO A; CARNEIRO J; ARALACHAVES M THE EFFECTS OF THALIDOMIDE TREATMENT ON AUTOIMMUNE-PRONE NZB AND MRL MICE ARE CONSISTENT WITH STIMULATION OF THE CENTRAL IMMUNE-SYSTEM .2. | 4 | 5 |
582 | 6 | 40 | 462 1995 HAUTARZT 46(8):553-560 DALLAFIOR S; PUGIN P; CERNY T; BETTICHER D; SAURAT JH; HAUSER C A CASE OF CUTANEOUS LANGERHANS CELL GRANULOMATOSIS SUCCESSFULLY TREATED WITH 2-CHLORODEOXYADENOSINE AND THALIDOMIDE | 4 | 9 |
583 | 2 | 4 | 496 1996 AMERICAN JOURNAL OF OPHTHALMOLOGY 122(4):594-595 Ip M; Gorin MB Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide | 4 | 13 |
584 | 2 | 5 | 547 1996 LANCET 347(9006):974-974 Verberkmoes A; Boer K; Wertheim PME; Bronkhorst CM; Lange JMA Thalidomide for genital ulcer in HIV-positive woman | 4 | 9 |
585 | 12 | 21 | 586 1997 CHEMTECH 27(1):21-25 Muller GW Thalidomide: From tragedy to new drug discovery | 4 | 9 |
586 | 3 | 9 | 587 1997 CLINICAL AND EXPERIMENTAL DERMATOLOGY 22(6):297-299 Darvay A; Basarab T; Russell-Jones R Thalidomide-induced toxic pustuloderma | 4 | 8 |
587 | 5 | 35 | 605 1997 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 19(3):313-326 Aseffa A; Dietrich MA; Shannon EJ Effect of thalidomide on apoptosis of lymphocytes and neutrophils | 4 | 5 |
588 | 5 | 19 | 661 1998 ANNALS OF INTERNAL MEDICINE 128(6):494-495 Ehrlich GE Behcet disease and the emergence of thalidomide | 4 | 19 |
589 | 6 | 10 | 691 1998 CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(5):233-235 Herranz P; Pizarro A; de Lucas R; Arribas JR; Garcia-Tobaruela A; Pena JM; Casado M Treatment of AIDS-associated prurigo nodularis with thalidomide | 4 | 5 |
590 | 15 | 33 | 741 1998 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 48(4):397-402 Zhu J; Deng GM; Diab A; Zwingenberger K; Bakhiet M; Link H Thalidomide prolongs experimental autoimmune neuritis in Lewis rats | 4 | 10 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
591 | 4 | 10 | 792 1999 CLINICAL INFECTIOUS DISEASES 28(4):892-894 Ramirez-Amador VA; Esquivel-Pedraza L; Ponce-de-Leon S; Reyes-Teran G; Gonzalez-Guevara M; Ponce-de-Leon S; Sierra-Madero JG Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: A double-blind placebo-controlled clinical trial | 4 | 5 |
592 | 7 | 33 | 810 1999 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 237(12):952-961 Joussen AM; Germann T; Kirchhof B Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency | 4 | 8 |
593 | 4 | 24 | 817 1999 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 80(1):11-16 Arrieta O; Ortiz-Reyes A; Rembao D; Calvillo M; Rivera E; Sotelo J Protective effect of pentoxifylline plus thalidomide against septic shock in mice | 4 | 8 |
594 | 13 | 49 | 958 2000 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 121(3):472-479 Guckian M; Dransfield I; Hay P; Dalgleish AG Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro | 4 | 6 |
595 | 40 | 51 | 997 2000 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 6(1):19-26 Lenardo TM; Calabrese LH The role of thalidomide in the treatment of rheumatic disease | 4 | 4 |
596 | 3 | 13 | 1021 2000 LIFE SCIENCES 67(4):457-461 Thiele A; Thormann M; Hofmann HJ; Naumann WW; Eger K; Hauschildt S A possible role of N-cadherin in thalidomide teratogenicity | 4 | 6 |
597 | 8 | 38 | 1043 2000 PAIN 88(3):267-275 George A; Marziniak M; Schafers M; Toyka KV; Sommer C Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin | 4 | 21 |
598 | 7 | 25 | 1060 2000 TETRAHEDRON LETTERS 41(37):7151-7155 Luzzio FA; Thomas EM; Figg WD Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine | 4 | 6 |
599 | 3 | 7 | 1070 2001 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(2):148-149 Esteve E; Legac E Deep vein thrombosis and pulmonary embolism in a patient with aphtosis treated with thalidomide | 4 | 4 |
600 | 21 | 30 | 1073 2001 ANNALS OF ONCOLOGY 12(7):885-886 Thomas DA; Kantarjian HM The revitalization of thalidomide | 4 | 5 |